Holli Dilks on Molecular Profiling

Holli Dilks, PhD
Published: Friday, Jun 12, 2015



Holli Dilks, PhD, Director, Personalized Medicine Operations Sarah Cannon Research Institute, discusses molecular profiling.

Clinical trial eligibility is often dependent on molecular status, but determining which patients should undergo molecular profiling and when can be challenging, said Dilks.

The National Comprehensive Cancer Network (NCCN) offers guideline that can help oncologists determine at which stage of disease patients should be profiled.

Reaching out to pharmaceutical partners to find out the eligibility criteria for patients to enroll can also help oncologists determine when molecular profiling is necessary.
 


Holli Dilks, PhD, Director, Personalized Medicine Operations Sarah Cannon Research Institute, discusses molecular profiling.

Clinical trial eligibility is often dependent on molecular status, but determining which patients should undergo molecular profiling and when can be challenging, said Dilks.

The National Comprehensive Cancer Network (NCCN) offers guideline that can help oncologists determine at which stage of disease patients should be profiled.

Reaching out to pharmaceutical partners to find out the eligibility criteria for patients to enroll can also help oncologists determine when molecular profiling is necessary.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x